比玛卢单抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "比玛卢单抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

1^st place

4^th place

5^th place

2^nd place

23^rd place

low place

9,985^th place

11^th place

332^nd place

low place

low place

3,538^th place

2,893^rd place

doi.org

Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O, et al. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clinical Endocrinology. June 2018, 88 (6): 908–919. PMID 29566437. S2CID 5019650. doi:10.1111/cen.13601.
Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. December 2014, 83 (24): 2239–2246. PMC 4277670 . PMID 25381300. doi:10.1212/WNL.0000000000001070.

Carroll J. Novartis' 'breakthrough' muscle drug bimagrumab flunks a late-stage trial. Fierce Biotech. 21 April 2016 [2023-12-04]. （原始内容存档于2023-12-04）.

Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O, et al. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clinical Endocrinology. June 2018, 88 (6): 908–919. PMID 29566437. S2CID 5019650. doi:10.1111/cen.13601.
Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. December 2014, 83 (24): 2239–2246. PMC 4277670 . PMID 25381300. doi:10.1212/WNL.0000000000001070.

Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM). Novartis AG. 23 August 2013 [20 August 2013]. （原始内容存档于19 February 2014）.
Novartis: Planned filings 2015 to >=2019 (PDF). Novartis Investor Presentation. 27 January 2015 [27 May 2015]. （原始内容 (PDF)存档于7 February 2015）.

GlobalData Healthcare. Versanis' bimagrumab, first-in-class obesity therapy, enters Phase IIb of development. Pharmaceutical Technology. 2023-01-17 [2023-05-27]. （原始内容存档于2023-11-20）（美国英语）.

Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O, et al. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clinical Endocrinology. June 2018, 88 (6): 908–919. PMID 29566437. S2CID 5019650. doi:10.1111/cen.13601.

GlobalData Healthcare. Versanis' bimagrumab, first-in-class obesity therapy, enters Phase IIb of development. Pharmaceutical Technology. 2023-01-17 [2023-05-27]. （原始内容存档于2023-11-20）（美国英语）.
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM). Novartis AG. 23 August 2013 [20 August 2013]. （原始内容存档于19 February 2014）.
Novartis: Planned filings 2015 to >=2019 (PDF). Novartis Investor Presentation. 27 January 2015 [27 May 2015]. （原始内容 (PDF)存档于7 February 2015）.
Carroll J. Novartis' 'breakthrough' muscle drug bimagrumab flunks a late-stage trial. Fierce Biotech. 21 April 2016 [2023-12-04]. （原始内容存档于2023-12-04）.
Medication shows promise for weight loss in patients with obesity, diabetes. EurekAlert!. [2021-01-20]. （原始内容存档于2021-04-08）（英语）.